Drug intelligence / Profile preview

PGSXC-T1D

Development stage: Preclinical
Lead developer: PrimeGen Biotech
Modality: Stem Cell Therapies → Cell Therapies

Overview

PGSXC-T1D is an investigational cell therapy being developed by PrimeGen for the treatment of Type 1 Diabetes Mellitus. It is based on the proprietary **stemXcell** platform, which utilizes "Triple Activated" Mesenchymal Stem Cells (MSCs). This platform is designed to enhance the natural immunomodulatory, anti-inflammatory, and paracrine signaling capabilities of MSCs. In the context of Type 1 Diabetes, PGSXC-T1D aims to suppress the autoimmune destruction of pancreatic beta cells and promote a pro-regenerative environment to restore or preserve insulin production. The program is currently in the preclinical stage of development.

Other names: stemXcellTriple Activated Mesenchymal Stem Cells

Beyond the preview

Go deeper on PGSXC-T1D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGSXC-T1D.

Explore the full profile